Epstein-Barr virus latent membrane protein 1 and 2-derived peptide antigen presented on MHC class I (EBV LMP1/LMP2-MHC I)

Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) and latent membrane protein 2 (LMP2) are essential viral proteins expressed during the latency phase of EBV infection (PMID: 25407441). These proteins play critical roles in cell transformation and the maintenance of viral episomes, contributing significantly to the development of EBV-associated malignancies such as nasopharyngeal carcinoma and various lymphomas (PMID: 17291317). Peptides derived from the proteasomal degradation of LMP1 and LMP2 are transported into the endoplasmic reticulum and loaded onto MHC class I molecules for presentation on the cell surface (PMID: 11160744). These peptide-MHC complexes serve as highly specific targets for the host's cellular immune response, particularly CD8+ cytotoxic T lymphocytes (PMID: 26179086). Therapeutic strategies targeting these antigens include adoptive transfer of EBV-specific T cells, such as Tabelecleucel, and TCR-engineered T cells designed to enhance the immune system's ability to identify and destroy EBV-positive tumor cells (PMID: 28438775). Because these antigens are predominantly expressed in infected or malignant cells, they offer a pathway for precision immunotherapy with potentially limited off-target effects on healthy tissues (PMID: 30633419).

Other names

EBV LMP1/2 peptide-HLA complexesLMP1/LMP2 epitopesEpstein-Barr virus latent membrane protein antigensEBV-specific T-cell targets

T-cell receptor (TCR) mediated recognition of viral epitopes presented by MHC class I molecules, leading to the activation of cytotoxic T lymphocytes and subsequent lysis of EBV-infected cells (PMID: 11160744).